

CASE STUDIES

Alzheimer's disease

Highlights:

- > 160% randomized at -32% cost per patient
- Over delivered randomized patients, using 64% of budget



CASE STUDY

Alzheimer's disease

160% randomized, at -32% cost per patient, for early Alzheimer's in 5 countries



Overview:

- Phase III study for patients aged 55-85 years old with early Alzheimer's disease
- Recruitment lasted 7 months, spanning Argentina, Australia, Belgium, Brazil, and South Africa
- Campaign extended to use remaining media budget to over deliver randomizations, ultimately reaching 160% of target

Our approach:

- Successfully piloted a point-based condition screener, which drove higher qualified referrals, ultimately increasing referral to consented conversion
- Using site feedback, we optimized the online screener, which resulted in a higher referral to consent conversion rate
- Phone screeners with protocol-trained team members managed the flow of referrals and engaged sites to ensure follow-up

Our results:



Randomizations vs. target



Increase of referral to consent rate vs. plan



Cost per randomization

CASE STUDY

Alzheimer's disease

Over delivered randomized patients, using 64% of budget



Overview & challenges:

- Online patient recruitment for phase II/ III Alzheimer's disease study
- Sponsor was looking for patients with mild cognitive impairment (MCI)
- 3-month recruitment campaign, across40 sites, in 5 countries
- Strict I/E criteria screened out >50% of patient registrations due to negative PET and too high RBAN score

Our approach:

- Online recruitment strategy, including online channels based on local demographics and target group
- Online & phone pre-screening ensured highly qualified subjects meeting the study's I/E criteria
- Active site support to contact, process, and enroll referred patients, increasing site efficiency and reducing cost per patient

Our results:



166%

Randomized patients vs. plan



1,740

Pre-screened referrals delivered in just 3 months



-36%

Reduced cost per randomized patient via ClinLife®

CLARINESS



Get in touch

Learn how we can support and scale your Alzheimer's disease study

CONTACT US

